P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy

Detalhes bibliográficos
Autor(a) principal: Cristelo, C.
Data de Publicação: 2022
Outros Autores: Gama, F. M., Sarmento, B.
Idioma: eng
Título da fonte: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Texto Completo: http://hdl.handle.net/1822/76419
Resumo: [Excerpt] Type 1 diabetes (T1D) is an autoimmune condition resulting in the destruction of the insulin-producing β cells. With no cure available for this disease, patients depend on insulin administration to control glycaemia. The recovery of β cells by promoting its replication, neogenesis or by reprogramming of other pancreatic cells, offers a promising strategy to revert T1D.
id RCAP_7dfb7c58d34dfe91e102edff48aed031
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/76419
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy[Excerpt] Type 1 diabetes (T1D) is an autoimmune condition resulting in the destruction of the insulin-producing β cells. With no cure available for this disease, patients depend on insulin administration to control glycaemia. The recovery of β cells by promoting its replication, neogenesis or by reprogramming of other pancreatic cells, offers a promising strategy to revert T1D.info:eu-repo/semantics/publishedVersionUniversidade do MinhoCristelo, C.Gama, F. M.Sarmento, B.2022-01-162022-01-16T00:00:00Zconference objectinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/1822/76419engCristelo, C.; Gama, F. M.; Sarmento, B., Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy. XIV Spanish-Portuguese Conference on Controlled Drug Delivery (Virtual Meeting). No. P3.2, Tenerife, Spain, Jan 26-28, 145, 2022.https://www.splc-crs.org/meeting-2022/info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-11T04:58:16Zoai:repositorium.sdum.uminho.pt:1822/76419Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T15:04:01.750097Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
title P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
spellingShingle P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
Cristelo, C.
title_short P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
title_full P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
title_fullStr P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
title_full_unstemmed P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
title_sort P3.2: Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy
author Cristelo, C.
author_facet Cristelo, C.
Gama, F. M.
Sarmento, B.
author_role author
author2 Gama, F. M.
Sarmento, B.
author2_role author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Cristelo, C.
Gama, F. M.
Sarmento, B.
description [Excerpt] Type 1 diabetes (T1D) is an autoimmune condition resulting in the destruction of the insulin-producing β cells. With no cure available for this disease, patients depend on insulin administration to control glycaemia. The recovery of β cells by promoting its replication, neogenesis or by reprogramming of other pancreatic cells, offers a promising strategy to revert T1D.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-16
2022-01-16T00:00:00Z
dc.type.driver.fl_str_mv conference object
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/76419
url http://hdl.handle.net/1822/76419
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cristelo, C.; Gama, F. M.; Sarmento, B., Targeted cathelicidin nanomedicines as novel glucoregulator for diabetes therapy. XIV Spanish-Portuguese Conference on Controlled Drug Delivery (Virtual Meeting). No. P3.2, Tenerife, Spain, Jan 26-28, 145, 2022.
https://www.splc-crs.org/meeting-2022/
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833595078236438528

Registros relacionados